Neuroprotective effects of maternal melatonin administration in early-onset placental insufficiency and fetal growth restriction

Pediatr Res. 2024 May;95(6):1510-1518. doi: 10.1038/s41390-024-03027-4. Epub 2024 Jan 15.

Abstract

Background: Early-onset fetal growth restriction (FGR) is associated with adverse outcomes. We hypothesised that maternal melatonin administration will improve fetal brain structure in FGR.

Methods: Surgery was performed on twin-bearing ewes at 88 days (0.6 gestation), and FGR induced in one twin via single umbilical artery ligation. Melatonin was administered intravenously (6 mg/day) to a group of ewes commencing on day of surgery until 127 days (0.85 gestation), when the ewe/fetuses were euthanized, and fetal brains collected.

Results: Study groups were control (n = 5), FGR (n = 5), control+melatonin (control+MLT; n = 6) and FGR+melatonin (FGR + MLT; n = 6). Melatonin administration did not significantly alter fetal body or brain weights. Myelin (CNPase+) fibre density was reduced in FGR vs. control animals in most brain regions examined (p < 0.05) and melatonin treatment restored CNPase fibre density. Similar but less pronounced effect was seen with mature myelin (MBP+) staining. Significant differences in activated microglia (Iba-1) activity were seen between lamb groups (MLT mitigated FGR effect) in periventricular white matter, subventricular zone and external capsule (p < 0.05). Similar effects were seen in astrogliosis (GFAP) in intragyral white matter and cortex.

Conclusions: Maternal melatonin administration in early onset FGR led to improved myelination of white matter brain regions, possibly mediated by decreased inflammation.

Impact: Maternal melatonin administration might lead to neuroprotection in the growth-restricted fetus, possibly via dampening neuroinflammation and enhancing myelination. This preclinical study adds to the body of work on this topic, and informs clinical translation. Neuroprotection likely to improve long-term outcomes of this vulnerable infant group.

MeSH terms

  • Animals
  • Brain* / drug effects
  • Brain* / pathology
  • Disease Models, Animal
  • Female
  • Fetal Growth Retardation* / drug therapy
  • Fetal Growth Retardation* / prevention & control
  • Melatonin* / administration & dosage
  • Melatonin* / pharmacology
  • Microglia / drug effects
  • Microglia / metabolism
  • Myelin Sheath / drug effects
  • Myelin Sheath / metabolism
  • Neuroprotective Agents* / administration & dosage
  • Placental Insufficiency* / drug therapy
  • Pregnancy
  • Sheep

Substances

  • Melatonin
  • Neuroprotective Agents